All Oncology News

The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.

Belantamab mafodotin met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial.

The frontline combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a robust and durable clinical benefit in patients with metastatic colorectal cancer.

The biosimilars realm of oncology has been surrounded by a burst of clinical and regulatory news this week, with the read out of phase III findings and extension data, legality issues, and more.

The Gayle and Tom Benson Cancer Center at Ochsner Medical Center (Benson Cancer Center) has again been granted Three-Year Accreditation with Commendation from The Commission on Cancer, a quality program of the American College of Surgeons.

Practice-changing phase III trials including KEYNOTE-189, KEYNOTE-407, REVEL, and IMpower131, among several others, are laying the groundwork for how to treat patients with non–small cell lung cancer, specifically on an individualized basis.

ABP 798, a rituximab (Rituxan) biosimilar, demonstrated clinical equivalency to reference rituximab in patients with CD20-positive B-cell non-Hodgkin lymphoma.

Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer.

The Japanese Ministry of Health, Labor and Welfare has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.

The FDA has granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with mantle cell lymphoma who have received ≥1 prior therapy.

Adjuvant treatment with the trastuzumab biosimilar CT-P6 demonstrated comparable efficacy and safety to the reference product in patients with HER2-positive early breast cancer.

Selinexor in combination with twice-weekly dexamethasone led to a median overall survival of 15.6 months in patients with heavily pretreated multiple myeloma who had a minimal response or better to the novel agent compared with 1.7 months in those whose disease progressed or had unevaluable responses.

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.

At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.

Madeleine B. Courtney Brooks, MD, MPH, sheds light on the current treatment paradigm of recurrent ovarian cancer.

The combination of durvalumab (Imfinzi) and tremelimumab did not improve overall survival versus standard platinum-based chemotherapy in previously untreated patients with stage IV metastatic non–small cell lung cancer.

Brian Orr, MD, discusses the challenges with immunotherapy in ovarian cancer treatment while pointing to early promising data with combination regimens.

Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.

John Comerci, Jr, MD, provides an overview of advances made in ovarian cancer and remaining challenges to address with future research.

Suresh A. Ramalingam, MD, discusses recent updates in EGFR-mutant non–small cell lung cancer and the next steps for osimertinib and other agents in this patient population.

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

A new drug application will be submitted to the FDA under accelerated approval status for lurbinectedin monotherapy for the second-line treatment of patients with small cell lung cancer, according to PharmaMar, the developer of the marine-derived agent.

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Kerry A. Rogers, MD, highlights the findings of a study examining acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia and the next steps for the data.

The FDA has approved fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

Treatment with the cryopreserved autologous tumor-infiltrating lymphocyte therapy lifileucel (LN-144) elicited a 38% objective response rate in heavily pretreated patients with metastatic melanoma.